Skip to main content

Table 1 Baseline characteristic data of the studied patients

From: Effect of sofosbuvir plus daclatasvir on virological response and liver function tests as a line of treatment for HCV related cirrhosis (a prospective cohort study)

VariablesStudied patients (N = 240)
Age 
 Mean ± SD52.9 ± 8.8 years
Gender 
 Male143 (59.6%)
 Female97 (40.4%)
Previous HCV treatment 
 Treatment naïve240 (100%)
 Treatment experienced0 (0.0%)
Viral load, IU/L 
 Median (IQR)5455685 (496040–18102824)
Fibroscan value, kPa 
 Mean ± SD25.8 ± 4.5
Serum ALT, IU/L 
 Median (IQR)62.5 (40.0–98.5)
Serum albumin, g/dL 
 Mean ± SD3.54 ± 0.46
Total bilirubin, mg/dL 
 Mean ± SD1.42 ± 0.60
INR 
 Mean ± SD1.19 ± 0.22
Child-Pugh score 
 Mean ± SD7.3 ± 1.5
Serum creatinine, mg/dL 
 Mean ± SD1.1 ± 0.3
AFP, ng/mL 
 Median (IQR)21.0 (18.0–30.0)
Platelet count, × 109 per liter 
 Mean ± SD131.5 ± 37.1
Treatment regimen 
 Sofosbuvir + daclatasvir240 (100.0%)
 Other regimens0 (0.0%)
Serious adverse effects0 (0.0%)
Discontinuation of treatment0 (0.0%)
  1. Data are presented as mean ± SD, median (IQR), or number (%)
  2. SD standard deviation, IQR interquartile range, HCV hepatitis C virus, ALT alanine aminotransferase, AFP alpha-fetoprotein, INR international normalization ratio